Drug intelligence / Profile preview

qingzao gegen yin

Development stage: Unknown
Lead developer: Shanghai Sixth People’s Hospital
Administration: Oral

Overview

Qingzao Gegen Yin is a traditional Chinese medicine (TCM) formulation administered orally and currently undergoing an exploratory clinical study. It is being investigated for its safety and preliminary effectiveness in advanced solid tumor patients who have developed grade II treatment-related liver damage. The formulation aims to sensitize the effects of concomitant treatments (Tianqingganmei and Yishanfu) and to mitigate liver injury.

Targets

GRIA2 (AMPA receptor subunit GluA2)

Beyond the preview

Go deeper on qingzao gegen yin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on qingzao gegen yin.

Explore the full profile